A panel of esteemed physicians review recent key data updates in ovarian cancer from ESMO 2022, including late-breaking news.
October 6th 2022
Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.
Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.
October 17th 2022
Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.
Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.
October 20th 2022
Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.
Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.
October 27th 2022
A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.
Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.
November 4th 2022
Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.
Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.
November 10th 2022
Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.
A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.
November 17th 2022
Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.
The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.